A multicentre, randomised controlled trial to compare the clinical and cost-effectiveness of Lee Silverman Voice Treatment versus standard NHS Speech and Language Therapy versus control in Parkinson’s disease: a study protocol for a randomised controlled trial

A multicentre, randomised controlled trial to compare the clinical and cost-effectiveness of Lee Silverman Voice Treatment versus standard NHS Speech and Language Therapy versus control in Parkinson’s disease: a study protocol for a randomised controlled trial

Abstract Background Parkinson’s disease (PD) affects approximately 145,519 people in the UK. Speech impairments are common with a reported prevalence of 68%, which increase physical and mental demands during conversation, reliance on family and/or carers, and the likelihood of social withdrawal redu...

Full description

Bibliographic Details
Main Authors: C. M. Sackley, C. Rick, P. Au, M. C. Brady, G. Beaton, C. Burton, M. Caulfield, S. Dickson, F. Dowling, M. Hughes, N. Ives, S. Jowett, P. Masterson-Algar, A. Nicoll, S. Patel, C. H. Smith, R. Woolley, C. E. Clarke, on behalf of the PD COMM Collaborative Group
Format: Article
Language:English
Published: BMC 2020-05-01
Series:Trials
Subjects:
Idiopathic Parkinson’s disease
Lee Silverman voice treatment
Speech and language therapy
Randomised controlled trial
Dysarthria
Online Access:http://link.springer.com/article/10.1186/s13063-020-04354-7

Internet

http://link.springer.com/article/10.1186/s13063-020-04354-7

Similar Items